Real-World Experience With Pacritinib in the US

CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/real-world-experience-with-pacritinib-in-the-us/26724/

Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.